{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Ramlakhan KP"],"funding":["Edwards Lifesciences","Boston Scientific Corporation","Fondazione Internazionale Menarini","Stichting Zabawas","Bristol-Myers Squibb","Amgen","De Hoop Foundation","Vifor Pharma","Pfizer","Novartis Pharma","Bayer","Gedeon Richter","Eli Lilly and Company","ResMed Foundation","Boehringer Ingelheim","Daiichi Sankyo Company","AstraZeneca","Servier","Sanofi","Abbott Vascular Int.","Merck Sharp and Dohme"],"pubmed_abstract":["<h4>Objective</h4>Pregnancy in women with aortic coarctation (CoA) has an estimated moderately increased risk (mWHO II-III) of adverse cardiovascular, obstetric or fetal events, but prospective data to validate this risk classification are scarce. We examined pregnancy outcomes and identified associations with adverse outcomes.<h4>Methods</h4>Pregnancies in women with CoA were selected from the worldwide prospective Registry of Pregnancy and Cardiac Disease (ROPAC, n=303 out of 5739), part of the European Society of Cardiology EURObservational Research Programme. The frequency of and associations with major adverse cardiac events (MACE) and hypertensive disorders (pregnancy-induced hypertension, (pre-)eclampsia or haemolysis, elevated liver enzymes and low platelets syndrome) were analysed"],"journal":["Heart (British Cardiac Society)"],"pagination":["heartjnl-2020-317513"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7873427"],"repository":["biostudies-literature"],"pubmed_title":["Pregnancy outcomes in women with aortic coarctation."],"pmcid":["PMC7873427"],"pubmed_authors":["Manga P","Tobler D","Johnson MR","Ramlakhan KP","Nihoyannopoulos P","Schwerzmann M","Hall R","Maggioni AP","Baris L","Greutmann M","Roos-Hesselink JW","ROPAC investigators group","Yetman AT","Boersma E"],"additional_accession":[]},"is_claimable":false,"name":"Pregnancy outcomes in women with aortic coarctation.","description":"<h4>Objective</h4>Pregnancy in women with aortic coarctation (CoA) has an estimated moderately increased risk (mWHO II-III) of adverse cardiovascular, obstetric or fetal events, but prospective data to validate this risk classification are scarce. We examined pregnancy outcomes and identified associations with adverse outcomes.<h4>Methods</h4>Pregnancies in women with CoA were selected from the worldwide prospective Registry of Pregnancy and Cardiac Disease (ROPAC, n=303 out of 5739), part of the European Society of Cardiology EURObservational Research Programme. The frequency of and associations with major adverse cardiac events (MACE) and hypertensive disorders (pregnancy-induced hypertension, (pre-)eclampsia or haemolysis, elevated liver enzymes and low platelets syndrome) were analysed","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2026-07-16T00:40:51.042Z","creation":"2026-07-09T10:25:58.677Z"},"accession":"S-EPMC7873427","cross_references":{"pubmed":["33122301"],"doi":["10.1136/heartjnl-2020-317513"]}}